Technology | Magnetic Resonance Imaging (MRI) | September 06, 2017

FDA Approves Guerbet's Dotarem for Pediatric Patients Younger Than Two Years

MRI contrast agent can now be used to detect disrupted blood brain barrier and/or abnormal vascularity of the central nervous system in youngest patients, including term neonates

FDA Approves Guerbet's Dotarem for Pediatric Patients Younger Than Two Years

September 6, 2017 — Guerbet LLC USA announced that the U.S. Food and Drug Administration (FDA) has approved Dotarem (gadoterate meglumine) for intravenous use with magnetic resonance imaging (MRI) in pediatric patients under two years old, including term neonates. The contrast agent can be used to detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system (CNS).

Dotarem was previously approved for this use in patient populations over the age of two.

This supplemental indication fulfills a post marketing requirement, acknowledged when Dotarem was first registered in March 2013, to strictly comply with the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c).

The FDA's review was based on a study showing that at the standard dose (0.1 mmol/kg),1 the pharmacokinetic (PK) and safety profiles in pediatric patients under two were similar to those of older children and adults.

The clinical study enrolled 51 pediatric patients in nine centers, with ages spanning from term neonates to 23 months and with normal renal function. It evaluated 45 pediatric patients for PK profile and safety, including five subjects aged less than one month and nine subjects aged one to three months. It assessed efficacy in a subset of 28 subjects who underwent an MRI examination of brain, spine and associated tissues.

In this pediatric population the observed safety profile of Dotarem was consistent with what has been reported in older populations. In one patient, rash was reported as a moderate adverse event (AE). Serious AEs unrelated to Dotarem were reported in one out of 45 patients. Evaluation of images from contrast-enhanced MRI of the CNS supported extrapolation of CNS efficacy findings reported in adults and older children.

Dotarem is the only macrocyclic and ionic gadolinium-based contrast medium (a kind that provides high molecular stability) available in the United States.

For more information: www.guerbet.com

Read the related article "Recent Trends and Developments in Contrast Media."
 

 

References

1. Dotarem (gadoterate meglumine) US Prescribing Information

Related Content

The Revolution Apex intelligent computed tomography (CT) scanner

The Revolution Apex intelligent computed tomography (CT) scanner. Image courtesy of GE Healthcare.

News | RSNA | October 18, 2019
At the 2019 annual meeting of the Radiological Society of North America (RSNA 2019), Dec. 1-6 in Chicago, GE Healthcare...
Guerbet Signs Agreement With Icometrix for Exclusive Distribution of Icobrain
News | Neuro Imaging | October 16, 2019
Guerbet announced it has signed an exclusive agreement with Icometrix for the distribution in France, Italy and Brazil...
Subtle Medical Receives FDA 510(k) Clearance for AI-powered SubtleMR
Technology | Artificial Intelligence | October 16, 2019
Subtle Medical announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market SubtleMR. SubtleMR...
Using Compressed SENSE for faster MRI scans, healthcare providers can transform their radiology workflow.

Using Compressed SENSE for faster MRI scans, healthcare providers can transform their radiology workflow.

Sponsored Content | Case Study | Magnetic Resonance Imaging (MRI) | October 16, 2019
Since the introduction of magnetic resonan...
Canon Medical Receives FDA Clearance for Vantage Orian 1.5T MRI

Canon Medical Receives FDA Clearance for Vantage Orian 1.5T MRI

Feature | Magnetic Resonance Imaging (MRI) | October 09, 2019 | By Jeff Zagoudis
Sponsored Content | Whitepapers | Clinical Trials | October 09, 2019
A 2019 N G PX REPORT
Patient Treatments With ViewRay's MRIdian Linac Begin in New England
News | Image Guided Radiation Therapy (IGRT) | October 08, 2019
ViewRay Inc. announced today that patient treatments are scheduled to begin in Boston with ViewRay's MRIdian Linac...
AI Accurately Detects Key Chest X-Ray Pneumonia Findings Within 10 Seconds
News | Artificial Intelligence | September 30, 2019
Researchers from Intermountain Healthcare and Stanford University say 10 seconds is about how quickly a new system they...
AI Accurately Predicts Radiotherapy Side Effects for Head and Neck Cancer Patients
News | Artificial Intelligence | September 26, 2019
For the first time, a sophisticated computer model has been shown to accurately predict two of the most challenging...
Machine Learning Could Offer Faster, More Precise Cardiac MRI Scan Results
News | Magnetic Resonance Imaging (MRI) | September 25, 2019
Cardiac magnetic resonance imaging (MRI) analysis can be performed significantly faster with similar precision to...